To explore the impact of Type I IFN signaling on T cell effector status, we treated tumor-bearing mice with an anti-IFNAR neutralizing antibody followed by SCRT and harvested CD8+ T cells for bulk RNA sequencing. This evidence concerns the gene IFNAR1 and neoplasm.